Brief: Matinas Biopharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug Mat2501
21/10/2021 12:48
Oct 21 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA INITIATES DOSING IN PHASE 1 STUDY OF
POTENTIAL
FIRST ORAL AMINOGLYCOSIDE ANTIBIOTIC DRUG MAT2501
Source text for Eikon: ID:nGNX3YTdbh
Further company coverage: MTNB.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing